| Date | Title | Description |
| 09.09.2026 | Neurent Medical Secures €25 Million Growth Debt Facility from Claret Capital Partners to Accelerate Commercial Expansion | Neurent Medical, the pioneer behind the NEUROMARK® System for the treatment of chronic rhinitis, today announced that it has secured a €25 million growth debt financing facility from Claret Capital Partners.
The financing will support the c... |
| 08.09.2026 | Priothera Appoints Experienced Biotech Executive, Dr Nigel Clark, as Chief Business Officer to Lead Strategic Partnering for Mocravimod | Priothera is the only company in advanced clinical development with a potential maintenance treatment for patients with acute myeloid leukaemia undergoing allogeneic hematopoietic cell transplantation
Priothera, a late-stage clinical biopha... |
| 05.08.2026 | MMI Receives FDA Approval to Advance to Phase II of Patient Enrollment in Groundbreaking REMIND Microsurgical Study in Alzheimer’s Patients | FDA-approved supplement advances early feasibility study (EFS) toward full enrollment
MMI (Medical Microinstruments, Inc.), a robotics company dedicated to increasing treatment options and improving clinical outcomes for patients with compl... |
| 10.07.2026 | MMI Completes World’s First Robotic Microsurgical Intracranial Brain Surgery | First-in-human cases lay the foundation for the next frontier in robotic microsurgery
MMI (Medical Microinstruments, Inc.), a robotics company dedicated to expanding treatment options and improving outcomes for patients with complex conditi... |
| 10.07.2026 | MMI Earns Gold Edison Award for Symani(R), Recognized for Expanding Access to Life-Changing Surgical Treatment Options | MMI (Medical Microinstruments, Inc.), a robotics company dedicated to expanding treatment options and improving outcomes for patients with complex conditions, today announced its Symani(R) Surgical System has earned the top award in the 202... |
| 10.07.2026 | NEUROMARK® Treatment for Chronic Rhinitis Demonstrates Durable 2-Year Clinical Benefits | PARAGON Study Confirms Sustained Efficacy and Safety of NEUROMARK® System in Allergic and Nonallergic Rhinitis Patients
Neurent Medical, a company pioneering innovative non-surgical interventions to treat chronic inflammatory sinonasal dise... |
| 10.07.2026 | XyloCor Therapeutics Raises $67.5 Million in Series B Financing to Advance Clinical Development of Novel Gene Therapy in Cardiovascular Disease | Financing round led by new investor Jeito Capital with participation from existing investors
Proceeds will support two double-blind Phase 2 clinical trials of lead candidate, XC001, which has demonstrated transformative potential for treatm... |
| 10.07.2026 | Vivasure Announces Positive Results of PATCH IDE Pivotal Study Indicating Safety and Efficacy of PerQseal® Large Hole Closure Device | Data from U.S. IDE PATCH Pivotal Study presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2024 annual conference will support a pre-market approval submission to the FDA
Results demonstrate Vivasure’s PerQseal® Closure Device ... |
| 10.07.2026 | Priothera Secures EUR1.7 million i-Nov Funding by Bpifrance for Rare Blood Cancer Clinical Program | Funding to support MOCART, a clinical programme evaluating mocravimod added to standard CAR-T cell therapy
Priothera, a late-stage biopharma company pioneering the development of mocravimod, a novel oral sphingosine 1 phosphate (S1P) recept... |
| 10.07.2026 | Lynkuet™ (elinzanetant) approved in the EU for the treatment of moderate to severe vasomotor symptoms associated with menopause or endocrine therapy for breast cancer | Elinzanetant, now approved in the EU under the brand name Lynkuet™ is a dual neurokinin (NK)-targeted therapy (NK-1 and NK-3 receptor antagonist) and the only hormone-free treatment for moderate to severe vasomotor symptoms (VMS; also known... |
| 10.07.2026 | XyloCor Appoints John Tucker as President and Chief Executive Officer | XyloCor Therapeutics, Inc. (XyloCor or the Company), a clinical-stage biopharmaceutical company focused on developing innovative therapies for cardiovascular disease, today announced the appointment of John Tucker as President and Chief Exe... |
| 10.07.2026 | First Patient Dosed in XyloCor Therapeutics’ Phase 2b EXACT-2 Trial Evaluating XC001 for the Treatment of Coronary Artery Disease | XC001 is a novel investigational therapy that previously demonstrated compelling efficacy and safety results, with disease-modifying potential, in patients with refractory angina in the EXACT-1 Phase 1/2 trial.
In the global EXACT-2 trial, ... |
| 10.07.2026 | Corteria Pharmaceuticals initiates Phase 2 trial in heart failure and Phase 1 trial in obesity with its first-in-class CRF2 agonists | CRAFT-WHF Phase 2 trial of COR-1167 initiated in patients with worsening heart failure
Phase 1 trial of COR-1389 ongoing in subjects with obesity
Corteria Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the developme... |
| 10.07.2026 | MMI’s Symani Surgical System Treats First Alzheimer’s Patient in Groundbreaking REMIND Study | FDA-IDE approved study enrolls first patient for robotic-assisted surgical intervention for neurodegenerative disease
MMI (Medical Microinstruments, Inc.), a robotics company dedicated to expanding treatment options and improving outcomes f... |
| 10.07.2026 | Bayer’s Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to Menopause | This approval is supported by data from the Phase III OASIS clinical trial program evaluating Lynkuet for the treatment of moderate to severe hot flashes due to menopause1
In OASIS 1 and OASIS 2, Lynkuet met the co-primary endpoints of redu... |
| 10.07.2026 | MMI Wins FDA Clearance and Completes First U.S. Clinical Use of Robotic Microsurgical Dissection Instruments with Symani | First U.S. Patient Treated with NanoWrist Dissection Instruments, Marking Early Clinical Adoption and Portfolio Growth
JACKSONVILLE, FL — December 9, 2025 — MMI (Medical Microinstruments, Inc.), a robotics company dedicated to expanding tre... |
| 10.07.2026 | Exciva doses first patient in Phase 2/3 trial of Deraphan for agitation in Alzheimer’s disease and extends Series B round | SERENADA trial to run at up to 60 sites across US, UK, Canada and Europe, targeting 300 patients
Exciva brings Series B round to €53M, with Dolby Ventures joining investor pool, and strengthens management with appointment of seasoned COO
Ex... |
| 10.07.2026 | Priothera Strengthens Board with Appointment of Industry Veteran, Dr. Hans Menssen | Highly experienced clinical development executive joins Priothera Board as mocravimod progresses through global Phase 3 trial as adjunctive and maintenance treatment in AML patients undergoing allo-HCT
Priothera Ltd., a late-stage biopharma... |
| 10.07.2026 | Neurent Medical Raises €62.5 million in Oversubscribed Series C Financing | Neurent Medical, the pioneer behind NEUROMARK®, an innovative, minimally invasive solution to treat chronic rhinitis, today announced the successful close of its oversubscribed Series C financing, raising €62.5 million ($74 million) to driv... |
| 10.07.2026 | Mainstay Medical Announces Coverage Recommendation from the International Society for the Advancement of Spine Surgery (ISASS) for ReActiv8 | Mainstay Medical Holdings plc today announced that the International Society for the Advancement of Spine Surgery (ISASS) has issued recommendations and coverage criteria for the use of restorative neurostimulation for the treatment of chro... |
| 10.07.2026 | Vivasure Medical Submits PMA Application for PerQseal® Elite and Secures Expanded Venous Indication in Europe | Regulatory progress underscores global momentum for PerQseal Elite in transforming large-bore vascular closure
Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced the su... |
| 10.07.2026 | Priothera Appoints Dr. Jens Hasskarl as Chief Medical Officer to Drive Late-Stage Clinical Development of Mocravimod, a S1P Receptor Modulator for Acute Myeloid Leukemia (AML) | Dr. Hasskarl to lead global Phase 3 MO-TRANS study evaluating mocravimod as an adjunctive treatment to allo-HCT in AML
Priothera Ltd., a late-stage biopharma company pioneering the development of mocravimod, a novel oral sphingosine 1 phosp... |
| 10.07.2026 | Haemonetics Acquires Vivasure Medical Limited | Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced the acquisition of Vivasure Medical Limited (Vivasure), a Galway, Irel... |
| 10.07.2026 | Neurent Medical Announces Publication of Positive Randomized Controlled Trial Results for the NEUROMARK® System | Study demonstrates superiority of radiofrequency posterior nasal nerve ablation versus sham control in patients with chronic rhinitis
Neurent Medical, a leader in non-surgical treatments for chronic rhinitis, today announced the publication... |
| 10.07.2026 | Exciva appoints distinguished biopharma leaderMark Altmeyer as chairman of the board | Strategic appointment underscores Exciva’s ambition to advance Deraphan, its lead product to treat agitation in Alzheimer’s patients, through late-stage development and global expansion
Exciva GmbH, a biopharmaceutical company developing no... |
| 10.07.2026 | MMI Introduces World’s First Microsurgical Suture for Robotics | New suture expands the Symani ecosystem, supporting greater efficiency and precision in robotic microsurgery
MMI (Medical Microinstruments, Inc.), a robotics company dedicated to increasing treatment options and improving clinical outcomes ... |
| 10.07.2026 | MMI Receives IDE Approval from FDA for First Robotic Microsurgical Study in Alzheimer’s Patients | First-of-its-kind study represents the potential for robotic-enabled microsurgical intervention for neurodegenerative diseases, including Alzheimer’s
MMI (Medical Microinstruments, Inc.), a robotics company dedicated to increasing treatment... |
| 10.07.2026 | Neuromod Closes €10m Financing to Accelerate Commercialisation | Financing led by existing investors Fountain Healthcare Partners and Panakès Partners
Neuromod will use funds to accelerate commercialisation in the USA and Europe.
Neuromod Devices Ltd. (Neuromod), an Irish medical device company specialis... |
| 10.07.2026 | Exciva raises €51 million ($59m) in Series B funding round | Exciva GmbH, a biopharmaceutical company developing novel therapeutic compounds for the treatment of neuropsychiatric conditions, today announces the closing of a €51 million ($59m) Series B financing round. Gimv and EQT Life Sciences co-le... |
| 10.07.2026 | Mainstay Medical Announces Positive Outcomes from Landmark RESTORE Clinical Trial of ReActiv8® | ReActiv8® Restorative NeurostimulationTM demonstrated statistically significant and clinically meaningful superiority vs. standard of care in all primary and secondary measures of disability, pain and quality of life
Safety profile consiste... |
| 10.07.2026 | Vivasure Medical Receives CE Mark Approval in Europe for PerQseal Elite Vascular Closure System | First fully absorbable, sutureless closure system designed for large-bore procedures aims to improve procedural efficiency and patient outcomes in structural heart interventions
Vivasure Medical®, a company pioneering novel fully absorbable... |
| 10.07.2026 | Neurent Medical Announces 510(k) Clearance of its Next Generation NEUROMARK® System | Developed in Collaboration with Leading ENT Experts, the Enhanced NEUROMARK® System Reflects Meaningful Innovation and Delivers Real-Time Feedback to Improve Patient Care
Neurent Medical, a leader in pioneering non-surgical solutions for ch... |
| 10.07.2026 | Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Anthem Blue Cross/Blue Shield | Mainstay Medical Holdings plc today announced that Anthem Blue Cross and Blue Shield (“Anthem”) has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic lo... |
| 03.05.2024 |
XyloCor Therapeutics Positive EXACT Phase 2 Data for XC001 Simultaneously Presented at SCAI 2024 Scientific Sessions and Published in Circulation: Cardiovascular Interventions | Positive Phase 2 EXACT Trial results validate transformative potential of novel gene therapy XC001 for treatment of refractory angina and support continued clinical development
Novel therapeutic approach aims to fill significant unmet medic... |
| 16.04.2024 |
Vivasure Medical Announces First Large Hole Venous Patient Treated with PerQseal Elite Vascular Closure System | Investigational technology designed for patients undergoing emerging large bore percutaneous catheter-based venous interventional procedures
Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel c... |
| 08.04.2024 |
MMI Receives FDA Authorization to Commercialize Symani® Surgical System in the U.S. | De Novo Classification builds on proven clinical success and expands global access to new category of treatments
MMI (Medical Microinstruments, Inc.), a robotics company dedicated to increasing treatment options and improving clinical outco... |
| 26.03.2024 |
Corteria Pharmaceuticals announces initiation of Phase 1 study to evaluate CRF2 agonist COR-1167 for treatment of worsening heart failure | Corteria Pharmaceuticals (‘Corteria’), a clinical-stage biopharmaceutical company focused on the development of transformative therapies for heart failure and obesity, today announces the initiation of its Phase 1 study to evaluate the comp... |
| 20.03.2024 |
Mainstay Medical Announces Publication of the First Neuromodulation Study for Low Back Pain with 5-Year Follow-Up | Groundbreaking ReActiv8-B study supports the long-term efficacy, safety and durability of ReActiv8® Restorative NeurostimulationTM for the treatment of intractable Chronic Low Back Pain
Mainstay Medical Holdings plc today announced the p... |
| 13.03.2024 |
Mainstay Medical Announces Publication of Clinical Results Comparing Older Patients and Younger Patients | Efficacy of ReActiv8® Restorative Neurostimulation™ shows no statistically or clinically meaningful differences between older and younger patient populations.
Mainstay Medical Holdings plc today announced the publication of a pooled anal... |
| 26.02.2024 |
Mainstay Medical Announces US$125 Million Equity Financing Transaction | Funding to accelerate commercial growth and expand clinical and health economic evidence for ReActiv8® Restorative NeuromodulationTM System
Mainstay Medical Holdings plc today announced an equity financing in which it will receive gross ... |
| 21.02.2024 |
MMI Raises $110 Million in Series C Financing | Largest ever investment in microsurgery will further MMI’s mission to transform open surgery with robotic technology
MMI (Medical Microinstruments, Inc.), a robotics company dedicated to increasing treatment options and improving clinica... |
| 13.02.2024 |
Mainstay Medical Announces Receipt of FDA Approval for MRI Labeling on ReActiv8® Restorative Neurostimulation SystemTM | U.S. patients implanted with ReActiv8 now eligible for full-body MRI scans
Mainstay Medical Holdings plc today announced that the U.S. Food and Drug Administration (FDA) has approved full-body MRI conditional labeling for the ReActiv8® R... |
| 08.01.2024 |
Inotrem Successfully Reaches Agreement with the FDA for a Phase 3 Registration Trial for Nangibotide in Septic Shock | Novel biomarker-guided Phase 3 registration trial in septic shock with an enrichment strategy-based patient selection.
Historic paradigm shift in Primary endpoint: from all causes of mortality at Day 29 to proportion of patients alive and ... |
| 08.01.2024 |
Calypso Enters into Agreement to Be Acquired by Novartis | Calypso is a European biotech translating Interleukin-15 biology into medical breakthroughs by developing CALY-002, an anti-IL-15 monoclonal antibody, for an array of autoimmune indications
The acquisition of Calypso gives Novartis full ri... |
| 06.01.2024 |
Corteria Pharmaceuticals appoints Mark Pruzanski as Chairman of its Board of Directors | Corteria Pharmaceuticals (“Corteria”), a biopharmaceutical company specialized in the development of transformative therapies for heart failure and obesity, today announced it has appointed Mark Pruzanski, MD, as Chairman of its Board of Di... |
| 27.11.2023 |
US FDA grants Orphan Drug Designation to mocravimod to improve the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with hematologic malignancies | Mocravimod is the only S1P receptor modulator being developed as an adjunctive and maintenance treatment for blood cancers
Mocravimod is being investigated in a global registration-enabling Phase 3 trial
This is the second Orphan Drug des... |
| 14.11.2023 |
Vivasure Medical Announces 100th Patient Enrolled in U.S. Pivotal Study | PATCH Clinical Study will evaluate the safety and efficacy of Vivasure’s PerQseal Closure Device System for large-bore vessel punctures
Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel clo... |
| 13.11.2023 |
Neurent Medical Announces New CPT Code® for Chronic Rhinitis Treatment Offering Significant Symptom Improvements | CMS Assignment Empowers ENT Physicians and Offers Relief to Millions of Chronic Rhinitis Patients
Neurent Medical, a company pioneering innovative non-surgical interventions to treat chronic inflammatory sinonasal diseases, today announc... |
| 19.10.2023 |
MMI Expands Global Footprint with Entry into Asia Pacific Market | Partnerships with Device Technologies and TRM Korea will strengthen Symani® Surgical System’s entrance into the world’s fastest-growing surgical robotics market.
MMI, (Medical Microinstruments, Inc.), a robotics company dedicated to incr... |
| 26.09.2023 |
MMI’s Symani® Robotic Surgical System Surpasses 500 Clinical Procedures | Milestone case performed at HUS Helsinki University Hospital demonstrates MMI’s continued momentum in the soft tissue open surgery field
MMI, (Medical Microinstruments, Inc.), a robotics company dedicated to increasing treatment options ... |
| 07.09.2023 |
Corteria Pharmaceuticals Announces a €65M Financing to Advance Transformational Medicines in Cardiovascular Diseases | Corteria Pharmaceuticals (“Corteria”), a biopharmaceutical company specialized in the development of transformative therapies for unaddressed heart failure subpopulations, today announced an oversubscribed €65M ($71M) Series A co-led by US ... |
| 29.08.2023 |
Mainstay Medical Announces Completion of Enrollment of RESTORE Clinical Trial of ReActiv8® in the United States | Randomized controlled clinical trial expected to validate effectiveness of ReActiv8® Restorative NeurostimulationTM vs. optimal medical management
Mainstay Medical Holdings plc today announced the completion of enrollment in its RESTORE ... |
| 25.08.2023 |
XyloCor Therapeutics Presents Phase 2 Data Highlighting Safety and Efficacy of XC001 at the European Society of Cardiology (ESC) Congress 2023 | Positive Phase 2 EXACT Trial results at 6-months underscore significant potential of investigational therapy in refractory angina
Six-month data have since been sustained out to 12-months supporting durability of XC001 safety and efficacy ... |
| 03.08.2023 |
Results from XyloCor Therapeutics’ Phase 1 Portion of EXACT Trial of XC001 for Cardiovascular Disease Published in Circulation: Cardiovascular Interventions | Findings from the Phase 1 dose escalation portion of the EXACT trial of XC001 in refractory angina provided the dose selection and safety justification for the recently completed Phase 1/2 study
XC001 is a one-time gene therapy candidate d... |
| 21.07.2023 |
Mainstay Medical Announces Publication of Three-Year Clinical Trial Data from Post-Market Clinical Follow-up Registry of ReActiv8® in the United Kingdom | Further real-world evidence supporting the efficacy and use of ReActiv8® Restorative NeurostimulationTM for the treatment of intractable Chronic Low Back Pain
Mainstay Medical Holdings plc today announced the publication of three-year cl... |
| 18.07.2023 |
XyloCor Therapeutics Reports Sustained Results in 12- Month Extension of Phase 2 EXACT Clinical Trial of XC001 Novel Gene Therapy for Refractory Angina | XC001 demonstrated durable improvements across multiple efficacy measures 12 months after treatment, underscoring its scientifically-sound approach to achieve biological effect and improve angina symptoms
Patients showed continued improvem... |
| 01.06.2023 |
Inotrem Announces Publication of Two Key Articles on Nangibotide Phase II Programs in Peer-reviewed Medical Journals | Data of ASTONISH Phase 2 trial in septic shock patients is published in The Lancet Respiratory Medicine and data of ESSENTIAL Phase 2 study in critically ill COVID-19 patients is published in eClinicalMedicine.
Both studies show that a the... |
| 15.05.2023 |
Dualyx raises €40 million to progress Treg therapies for autoimmune diseases into the clinic | Use of proceeds will enable the development of the Company’s lead autoimmune program DT-001, targeting TNFR2, as well as its pipeline of Treg candidates
Financing co-led by Fountain Healthcare Partners, Forbion and Andera Partners with sup... |
| 14.04.2023 |
Neuromod Devices Closes €30 Million Financing to Expand Availability of Tinnitus Treatment Device Lenire® | Equity investment led by Panakès Partners with venture debt provided by European Investment Bank
Financing round follows recent US FDA granting of De Novo approval to Neuromod's Lenire tinnitus treatment device
Neuromod Devices Ltd, an ... |
| 21.03.2023 |
New Data show NEUROMARK® Chronic Rhinitis Treatment Offers Significant Symptom Improvements | Results from the CLARITY Study Show the NEUROMARK® System Provides Safe and Effective Treatment for Patients with Chronic Rhinitis
Neurent Medical, a company pioneering innovative non-surgical interventions to treat chronic inflammatory ... |
| 13.03.2023 |
Vivasure Medical Announces FDA IDE Approval to Initiate U.S. Pivotal Study | Pivotal study expected to be completed by year-end 2023 and set the stage for commercialization of PerQseal® system for large hole vessel closure
Company announces €30 million strategic investment from Haemonetics as part of its previously... |
| 07.03.2023 |
FDA Grants Lenire® Tinnitus Treatment Device De Novo Approval | Neuromod Devices' non-invasive device, Lenire, is the first of its kind granted approval to treat tinnitus in the US market.
At least 25,000,000 Americans are suffering from tinnitus, 2,700,000 are veterans.
FDA approval based on results ... |
| 03.02.2023 |
Neurent Medical Announces Limited Market Release of NEUROMARK® System to Treat Chronic Rhinitis | NEUROMARK received new Category I CPT code and support from AAO position statement
Neurent Medical, a company pioneering innovative non-surgical interventions to treat chronic inflammatory sino-nasal diseases, today announced its NEUROMA... |
| 26.01.2023 |
XyloCor Therapeutics Reports Positive Topline Safety and Efficacy Results from Phase 2 EXACT Clinical Trial of XC001 Novel Gene Therapy for Refractory Angina | No serious adverse events related to drug product were reported
Patients demonstrated improvements in exercise capacity and reductions in episodes of chest pain
Cardiac imaging results provide mechanistic evidence supporting the therapeut... |
| 23.01.2023 |
Priothera announces first patients enrolled in pivotal MO-TRANS global Phase 2b/3 study with mocravimod as an adjunctive and maintenance therapy for patients with AML undergoing allogeneic HCT | Mocravimod is the only S1PR modulator being developed to treat blood cancers and improve CAR-T therapy
Phase 1b/2a data has shown mocravimod is safe and well tolerated
Priothera, a late-clinical stage biotechnology company pioneering th... |
| 09.01.2023 |
Inotrem Receives Funding from the Crohn’s & Colitis Foundation to help develop new therapeutic approaches in Inflammatory Bowel Disease (IBD) | The funding will support the development of INO-02 a new long-acting therapeutic approach to modulate the TREM-1 pathway.
Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammato... |
| 16.12.2022 |
Calypso Biotech Announces First Patient with Eosinophilic Esophagitis Dosed in Anti-Interleukin-15 (IL-15) Monoclonal Antibody CALY-002 Phase 1a/b Trial, and Animal POC Data in Atopic Dermatitis | Healthy volunteers phase completed showing differentiating target engagement biomarker data and favorable safety data
On track for top-line histology data in 2023 in Celiac Disease and Eosinophilic Esophagitis
Proof-of-concept data of CAL... |
| 25.10.2022 |
Inotrem Announces That Its ESSENTIAL Phase II Study for the Treatment of Critically ill COVID-19 Patients Meets Its Primary and Key Secondary Endpoints |
Inotrem, an advanced clinical stage biotech company specializing in immunotherapies for acute and chronic inflammatory syndromes, announced today at the European Society of Intensive Care Medicine’s Annual Congress, held in Paris, positiv... |
| 21.10.2022 |
Corteria Pharmaceuticals strengthens its Executive Leadership Team, Board of Directors, and Scientific Advisory Board | Corteria Pharmaceuticals, a biotechnology company developing innovative treatments for certain forms of heart failure, announced today the recruitment of Dr. Francesca C. Lawson as Chief Medical Officer. Corteria Pharmaceuticals also expand... |
| 13.10.2022 |
Inotrem announces the outcome of its Phase II ASTONISH trial in septic shock patients demonstrating efficacy of nangibotide |
Inotrem, an advanced clinical stage biotech company specializing in immunotherapies for acute and chronic inflammatory syndromes, disclosed for the first time today at the International Sepsis Forum held in Barcelona the results for its P... |
| 30.09.2022 |
Mainstay Medical Announces Publication of Three-Year Patient Outcomes Data from ReActiv8-B Clinical Trial Demonstrating Long-Term Efficacy of ReActiv8® Restorative Neurostimulation™ |
Mainstay Medical Holdings plc today announced the publication of the three-year patient outcomes data from its pivotal ReActiv8-B clinical trial. The data, published in the journal of the International Neuromodulation Society, Neuromodula... |
| 23.09.2022 |
United Kingdom National Institute for Health and Care Excellence (NICE) Publishes Interventional Procedure Guidance (IPG) for ReActiv8® Restorative Neurostimulation™ | Mainstay Medical Holdings plc announced today that the National Institute for Health and Care Excellence (NICE), a public body of the Department of Health that carries out evidence-based health technology assessments by independent committe... |
| 20.07.2022 |
Medical Microinstruments Secures $75M to Advance Robotic Microsurgery |
Medical Microinstruments, Inc. (MMI), a robotics company dedicated to improving clinical outcomes for patients undergoing microsurgery, today announced it has raised $75 million in Series B financing. Deerfield Management led the round wi... |
| 30.06.2022 |
Ermium Therapeutics extends its initial €6.3 M funding to €12.3 M to further advance breakthrough auto-immune disease therapeutics | Ermium Therapeutics, a Paris-based biotech company developing innovative health products for auto-immune diseases, announced today the extension of its initial funding of €6.3 M to €12.3 M with Kurma Partners and Fountain Healthcare Partner... |
| 28.06.2022 |
XyloCor Therapeutics Achieves Target Enrollment in Phase 2 EXACT Study of XC001 Novel Gene Therapy for Ischemic Heart Disease |
XyloCor Therapeutics, a clinical-stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, today announced it has achieved enrollment of target number of subjects in the Phase 2 portion of its ongoing Pha... |
| 13.06.2022 |
Clinical Mocravimod Data in Hematological Malignancies Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (aHSCT) Presented at the 2022 EHA Congress |
Priothera, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator compound, mocravimod, presented first clinical data on mocravimod (also known as KRP203) in hematological malignancies patient... |
| 01.06.2022 |
Priothera Receives Fast Track Designation for mocravimod in Combination with Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Post Remission Therapy of Acute Myeloid Leukemia (AML) Patients | Priothera, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator compound, mocravimod, today announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) ... |
| 31.05.2022 |
Inotrem announce the appointment of Luke Beshar as Chairman of Board of Directors | Inotrem, an advanced clinical stage biotech company developing TREM- 1 targeting immunotherapies for acute and chronic inflammatory syndromes, announced today the appointment of Luke Beshar as Chairman of its Board of Directors, effective M... |
| 26.05.2022 |
Medical Microinstruments Launches New Simulator for Robotic Microsurgery |
Medical Microinstruments (MMI) SpA, a robotics company dedicated to improving clinical outcomes for patients undergoing microsurgery, today announced the launch of its Symani Surgical System Simulator developed by VirtaMed. The simulator ... |
| 18.05.2022 |
XyloCor Therapeutics Announces Presentation of Preliminary Clinical Data from Phase 1 Portion of the EXACT Phase 1/2 Study of XC001 Novel Gene Therapy for Refractory Angina at AATS and ASGCT |
XyloCor Therapeutics, a clinical‑stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, today announced presentation of initial clinical data from the Phase 1 portion of its ongoing Phase 1/2 clinical ... |
| 18.05.2022 |
Medical Microinstruments Announces Major Expansion in Pisa, Italy to Support Growth |
Medical Microinstruments (MMI) SpA, a robotics company dedicated to improving clinical outcomes for patients undergoing microsurgery, today announced the grand opening of its new facility in Pisa, Italy. MMI consolidated locations through... |
| 17.05.2022 |
Vivasure Medical Announces Series D Financing to Advance Portfolio of PerQseal Vessel Closure Devices |
Vivasure Medical® (“Vivasure” or the “Company”), a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced the closing of the first tranche of €22 million ($23M) as part of its Series D financ... |
| 25.04.2022 |
Priothera Receives FDA clearance of IND to start Phase 2b/3 study with mocravimod in Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HSCT) |
Priothera Ltd, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator compound, mocravimod, today announces that the U.S. Food and Drug Administration (FDA) has provided clearance to proceed w... |
| 20.04.2022 |
Vivasure Medical Begins Clinical Evaluation of Next-Generation PerQseal+ Device | Vivasure Medical® today announced the first patient was enrolled in the Frontier V study, a European multicenter study evaluating PerQseal®+, the next generation of the company’s PerQseal® device. The patient was enrolled by Dr. Fernando Ga... |
| 14.04.2022 |
Inotrem and the Crohn’s & Colitis Foundation Sign a R&D Collaboration Agreement to Support the Development of a New Therapeutic Approach in Inflammatory Bowel Disease (IBD) |
Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today a R&D collaboration agreement with the Crohn’s & Colitis Foundation to support the de... |
| 12.04.2022 |
Priothera Receives First Regulatory Approvals to Start a Global Pivotal Study with Mocravimod in Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant |
Priothera Ltd, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator mocravimod, today announces it has received the two first European country approvals from the Swiss and French national he... |
| 06.04.2022 |
Neuromod establishes global commercial leadership team |
Neuromod Devices Ltd. has announced the formation of a global commercial leadership team to direct the commercialisation of its Lenire tinnitus treatment device through key partnerships.
The establishment of the team sees the organisatio... |
| 04.03.2022 |
Priothera – FDA and EMA Grant Orphan Drug Designation to mocravimod for the treatment of Acute Myeloid Leukemia (AML) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT)... |
Priothera, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator drug, mocravimod, today announced that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) hav... |
| 01.03.2022 |
AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio |
AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of... |
| 23.02.2022 |
Priothera Enters Loan Agreement of €17.5 Million with the European Investment Bank |
Priothera, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator drug, mocravimod, today announces that it has entered a Loan Agreement of €17.5 million with the European Investment Bank (EIB... |
| 18.01.2022 |
XyloCor Therapeutics Expands Leadership Team with Accomplished Pharmaceutical Executives to Accelerate Clinical Development Programs and Drive Corporate Growth |
XyloCor Therapeutics, a clinical‑stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, today announced that it has appointed Elizabeth Tarka, M.D. as Chief Medical Officer and A. Brian Davis as Chief ... |
| 14.01.2022 |
Neuromod launches Ótologie to provide specialist care service for tinnitus patients | Irish medical device company, Neuromod Devices Ltd, has launched Ótologie, a specialist healthcare service for people living with tinnitus. This new service will enable tinnitus patients, in Ireland and throughout Europe, to avoid waiting l... |
| 07.01.2022 |
Mainstay Medical Announces Publication of Two-Year Patient Outcomes Data from ReActiv8-B Clinical Trial Demonstrating Long-Term Efficacy of ReActiv8® Restorative Neurostimulation™ |
Mainstay Medical Holdings plc today announced the publication of the two-year patient outcomes data from its pivotal ReActiv8-B clinical trial. The data, published in the journal of the International Neuromodulation Society, Neuromodulati... |
| 14.12.2021 |
Mainstay Medical Announces Appointment of Jeffrey Dunn and Eric Major to its Board of Directors | Mainstay Medical Holdings plc today announced the appointment of two new independent members to the company’s board of directors, Jeffrey Dunn and Eric Major. These appointments bring Mainstay’s total board membership to seven.
“We are ple... |
| 25.11.2021 |
Priothera Appoints Elisabeth Kueenburg M.D., as Chief Medical Officer | Priothera Limited, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator compound, mocravimod, announces the appointment of Elisabeth Kueenburg, M.D., as Chief Medical Officer. Dr. Kueenburg wi... |
| 18.11.2021 |
Neurent Medical Receives FDA Clearance for NEUROMARK™, a Novel Multi-Point Nerve Disruption Treatment for Chronic Rhinitis |
Neurent Medical, a company pioneering innovative treatments for chronic inflammatory sino-nasal diseases, today announced Food and Drug Administration (FDA) clearance of its proprietary NEUROMARK™ Rhinitis Neurolysis Therapy™ (RNT). The c... |
| 09.11.2021 |
Inotrem appoints Dr. Gregory Meiffren as Project Director for its Antibody-based R&D Program Targeting Chronic Inflammatory Diseases | Inotrem, an advanced clinical stage biotech company specialized in immunotherapies targeting the TREM-1 pathway, announced today the appointment of Dr. Gregory Meiffren as Project Director for its Antibody-based R&D Program. The creatio... |
| 27.10.2021 |
Neuromod appoints Teri Minard to lead introduction of tinnitus treatment medical device to US Veterans | Neuromod Devices Ltd, the medical device company which specialises in neuromodulation technologies, has announced the appointment of Ms. Teri Minard as Director, Government Sales of its recently established US entity, Neuromod USA Inc.
As ... |
| 21.10.2021 |
Syndesi Therapeutics announces commencement of dosing in clinical trial of SDI-118 in elderly subjects with cognitive impairment | Syndesi Therapeutics SA, a clinical stage biotechnology company developing novel modulators of the synaptic vesicle protein SV2A for the treatment of cognitive impairment, announces that dosing has commenced in the first clinical trial in t... |
| 13.09.2021 |
Neuromod appoints Eric Timm as US Chief Executive Officer | Neuromod Devices Ltd, the medical device company which specialises in neuromodulation technologies, has announced the appointment of Mr. Eric Timm as Chief Executive Officer of its recently established US entity, Neuromod USA Inc., effectiv... |